CO-DIAGNOSTICS, INC. Form 8-K (Aug. 11, 2022)

Summary

Current report on Form 8-K of Co-Diagnostics, Inc. reporting an event dated August 11, 2022. Under Item 2.02 the company states that it issued a press release announcing financial results for its quarter ended June 30, 2022, furnished as Exhibit 99.1, which includes information regarding its use of a non-GAAP financial measure. The filing says the information is furnished and not deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934. Item 7.01 incorporates the Item 2.02 information by reference. /s/ Brian Brown, Chief Financial Officer, signed August 11, 2022.

Summary drafted by a model from the document's text below and checked by script against that text before publication. It is a navigation aid, not a reading of what the document proves. Where AI is used

Full text

UNITED
STATES

SECURITIES
AND EXCHANGE COMMISSION

Washington,
D.C. 20549

FORM 8-K

CURRENT
REPORT

Pursuant
to Section 13 or 15(d) of the

Securities
Exchange Act of 1934

Date
of report (Date of earliest event reported): August 11, 2022

CO-DIAGNOSTICS,
INC.

(Exact
name of small business issuer as specified in its charter)

Utah | 1-38148 | 46-2609363
(State or other jurisdiction
 of | (Commission | (IRS Employer
incorporation or organization) | File Number) | Identification Number)

2401
S. Foothill Drive , Suite D , Salt Lake City , Utah 84109

(Address
of principal executive offices)

(801) 438-1036

(Issuer’s
telephone number)

Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions:

☐ | Written communications
 pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ | Soliciting material pursuant
 to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ | Pre-commencement communications
 pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ | Pre-commencement communications
 pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities
registered pursuant to Section 12(b) of the Act:

Title
 of each class | Trading
 Symbol(s) | Name
 of each exchange on which registered
Common Stock, par value
 $0.001 per share | CODX | The Nasdaq Capital Market

Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging
growth company ☒

If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item
2.02. Results of Operations and Financial Condition.

On
August 11, 2022, Co-Diagnostics, Inc. (the “Company”) issued a press release announcing financial results for its quarter
ended June 30, 2022. The full text of the press release, which includes information regarding the Company’s use of a non-GAAP financial
measure, is furnished as Exhibit 99.1 to this Form 8-K.

The
information contained in this Item 2.02, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed to be “filed”
for the purposes of Section 18 of the Securities Exchange Act of 1934, or otherwise subject to the liabilities of that section. Furthermore,
the information contained in this Item 2.02 or Exhibit 99.1 shall not be deemed to be incorporated by reference into any registration
statement or other document filed pursuant to the Securities Act of 1933, except as shall be expressly set forth by specific reference
in such filing.

Item
7.01. Regulation FD. Disclosure.

The
information set forth under Item 2.02 is incorporated by reference as if fully set forth herein.

Item
9.01 Financial Statements and Exhibits.

(d)
Exhibits

Exhibit
 No.: | Description:
99.1 | Press Release, dated August 11, 2022
104 | Cover Page Interactive
 Data File (embedded within the Inline XBRL document)

SIGNATURE

Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned, hereunto duly authorized.

CO-DIAGNOSTICS, INC.
Date: August 11, 2022 | By: | /s/
 Brian Brown
Name: | Brian Brown
Title: | Chief
 Financial Officer (Principal
 Financial and Accounting Officer)

File and source

File

SEC_CODX_8-K_filed2022-08-11_0001493152-22-022067.htm

Size

38,437 bytes

SHA-256

ac0fcbcd2967645944a1c7ca5c6fce22a49c11accacc61fa5c2f48cd8c9fde96

Our copy

SEC_CODX_8-K_filed2022-08-11_0001493152-22-022067.htm

Original

www.sec.gov